PIK3CA Mutation Correlates With mTOR Pathway Expression But Not Clinical and Pathological Features in Fibro-Adipose Vascular Anomaly (FAVA)

Yumiko Hori

Osaka University: Osaka Daigaku

Katsutoshi Hirose

Osaka University: Osaka Daigaku <https://orcid.org/0000-0003-4148-1106>

Michio Ozeki

Gifu University: Gifu Daigaku

Kenji Hata

Osaka University: Osaka Daigaku

Daisuke Motooka

Osaka University: Osaka Daigaku

Shinichiro Tahara

Osaka University: Osaka Daigaku

Takahiro Matsui

Osaka University: Osaka Daigaku

Masaharu Kohara

Osaka University: Osaka Daigaku

Hiroki Higashihara

Osaka University: Osaka Daigaku

Yusuke Ono

Osaka University: Osaka Daigaku

Kaishu Tanaka

Osaka University: Osaka Daigaku

Satoru Toyosawa

Osaka University: Osaka Daigaku

Eiichi Morii (✉ morii@molpath.med.osaka-u.ac.jp)

Osaka University Graduate School of Medicine

Short report

Keywords: Fibro-adipose vascular anomaly, FAVA, PIK3CA, mTOR, Vascular anomaly, Lymphatic malformation, Venous malformation, Sirolimus

Posted Date: October 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-966735/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

Fibro-adipose vascular anomaly (FAVA) is a rare and new entity of vascular anomaly. Activating mutations in the *phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha* (*PIK3CA*) gene were identified at a frequency of 62.5% in FAVA cases. The *PIK3CA* mutations excessively activate mammalian target of rapamycin (mTOR) pathway, which promotes angiogenesis and lymphangiogenesis, implying that *PIK3CA* mutations may act as drivers of FAVAs. This study investigated the correlations between *PIK3CA* mutational status, clinicopathological features and immunohistochemical expression of the mTOR pathway in a series of FAVA.

Methods

We retrospectively evaluated the clinical and pathological findings of five FAVA cases. We performed next-generation sequencing (NGS) with a custom panel of genes associated with the mTOR pathway and genes responsible for other vascular anomalies, direct sequencing and immunohistochemical analysis of the mTOR pathway.

Results

Two *PIK3CA*-mutation cases and three *PIK3CA*-wild-type (wt) cases exhibited similar typical clinical features of FAVA. Histological analysis revealed venous malformation, lymphatic malformation, nerves containing enlarged abnormal vessels and fibrofatty tissue were observed regardless of *PIK3CA* mutational status. In contrast to clinical and histological findings, the immunohistochemical expression of activated AKT and mTOR that are upstream of the mTOR pathway was detected in abnormal vessels of *PIK3CA*-mutation cases but not in those of *PIK3CA*-wt cases. However, activated eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1), both of which are downstream effectors of the mTOR pathway, were expressed in abnormal vessels of both *PIK3CA*-mutation and *PIK3CA*-wt cases. Furthermore, targeting NGS did not find any common genetic mutations involved in the mTOR pathway among *PIK3CA*-wt cases.

Conclusion

There was no significant association between the presence of *PIK3CA* mutations and the clinicopathological features of FAVA, suggesting that the *PIK3CA* gene is not necessarily involved in the onset of FAVA. FAVAs lacking *PIK3CA* mutations would be caused by other gene mutations that activate 4EBP1 and S6K1.

Background

Fibro-adipose vascular anomaly (FAVA) is a new entity of vascular anomaly [1]. FAVA is extremely rare and occurs most commonly in the muscles of the lower extremities of young patients [1, 2]. Histologically, FAVA is composed of venous malformation (VM), lymphatic malformation (LM), and the presence of fibro-adipose tissues with the atrophic skeletal muscle [1, 3]. A recent study identified somatic and mosaic gain-of-function mutations of the *phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha* (*PIK3CA*) gene in a

subset of FAVAs (62.5%) [4]. The identified *PIK3CA* mutations are p.E542K, p.E545K and p.Q546K in the helical domain (encoded within exon 9), and p.H1047R in the kinase domain (encoded within exon 20) [4]. These *PIK3CA* mutations are termed hotspot mutations, and are present in a subset of VMs and the majority of LMs [4–10]. *PIK3CA* mutations excessively activate the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in the endothelial cells during vascular malformations [4–10]. Activation of PI3K results in the phosphorylation of AKT (p-AKT), and p-AKT phosphorylates mTOR. Furthermore, the phosphorylated form of mTOR (p-mTOR) phosphorylates downstream effectors such as eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1), ultimately promoting angiogenesis and lymphangiogenesis [11, 12]. These results highly suspected that *PIK3CA* mutations may act as drivers of FAVAs through activation of the PI3K/AKT/mTOR pathway. Furthermore, the presence of *PIK3CA* mutations in VMs and the genotype of *PIK3CA* mutation in LMs correlate with both clinical severity and histological features [8, 10, 13]. However, little is known regarding the correlations among *PIK3CA* mutational status, the mTOR pathway activation status and clinicopathological features in FAVA. Here, we report the results of clinical, histological, immunohistochemical, and genetic analyses examining a small series of isolated FAVA cases.

Methods

Five FAVA cases with formalin-fixed paraffin-embedded (FFPE) tissues were retrieved from the pathology files of Osaka University Hospital from 2010 to 2020. A final diagnosis of FAVA was determined by consensus agreement after consideration of clinical, radiologic, and histological findings [1-3]. This study was approved by the Ethical Review Board of the Graduate School of Medicine, Osaka University (IBR No. 17214).

Next-generation sequencing (NGS)

Genomic DNA was extracted from FFPE tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The gene panel was designed by SureDesign (<https://earray.chem.agilent.com/suredesign>) to cover a whole exon of 14 genes associated with the mTOR pathway signaling or responsible for other vascular anomalies (*PIK3CA*, *TEK*, *GNA11*, *GNAQ*, *AKT1*, *PTEN*, *mTOR*, *CCM*, *BRAF*, *MAP3K3*, *KRAS*, *NRAS*, *HRAS*, *RASA1*). On average 70 ng of the extracted DNA was fragmented by SureSelect Fragmentation Enzyme (Agilent Technologies, Inc. Santa Clara, CA, USA) to 150–200 bp. Sequence libraries were prepared with a custom SureSelect Low Input Target Enrichment System (Agilent Technologies, Inc. Santa Clara, CA, USA) according to the manufacturer's instructions and sequenced with the Illumina MiSeq (Illumina, San Diego, CA, USA). SureCall ver4.0 (<https://www.agilent.com/en/download-software-surecall>) was used for variant calling. DNA in introns or non-coding DNA were excluded. To confirm *PIK3CA* gene mutations, polymerase chain reaction (PCR) assays and direct sequencing were performed using the following primers: PIK3CA-Exon9 Forward, CAGCTCAAAGCAATTTCTAC; PIK3CA-Exon9 Reverse, CACTTACCTGTGACTCCAT; PIK3CA-Exon20 Forward, AACTGAGCAAGAGGCTTTGG; PIK3CA-Exon20 Reverse, TGTGTGGAAGATCCAATCCA. A mixture of 5% PIK3CA-mutant DNA against a background of 95% wild-type (wt) DNA was used as a positive control.

Histological and Immunohistochemical staining

Resected tissue samples were fixed with 10 % formalin, routinely embedded in paraffin, cut into 4 µm thick serial sections, and used for H&E and immunohistochemical staining. Immunohistochemical staining was performed using a Roche Ventana BenchMark GX autostainer (Ventana Medical Systems, Tucson, AZ, USA) according to the manufacturer's instructions. Primary antibodies against p-AKT (#4060, 1:100; Cell Signaling Technology, Danvers, MA, USA), p-mTOR (clone 49F9, 1:100; Cell Signaling Technology), p-S6K1 (#9204, 1:100; Cell Signaling Technology), p-4EBP1 (clone 236B4, 1:500; Cell Signaling Technology), S100 (polyclonal, Ventana Medical Systems), CD31 (clone JC70A, 1:200, Dako), CD34 (clone QBEnd10, 1:200, Dako), D2-40 (760-4395, Ventana Medical System), and PROX1 (ab199359, 1:500; Abcam, Cambridge, UK) were used. Samples were considered positive when at least 10% of the endothelial cells of abnormal vessels exhibited a signal for the targeted protein.

Results

Clinical data and molecular genetic findings

The five patients included four men and one woman, and they ranged in age from 3 to 72 years (median, 13 years). Two patients presented at birth (cases 1 and 3). The presenting symptoms were pain (5/5 cases), swelling (4/5 cases), and functional restriction (2/5 cases). The preoperative clinical diagnosis was vascular anomalies, including infantile hemangioma, vascular malformation, and FAVA. The lesions were located within and in the vicinity of the thigh muscles, soleus muscle, and knee (Fig. 1A-E). Heterogenous *PIK3CA* hotspot mutation (p.H1047R) was identified in two cases (cases 1 and 2) (Fig. 1F), while none of the *PIK3CA* mutations were detected in other three cases (cases 3-5) (Fig. 1G). We also found mutations in *TEK* in 2 cases, *GNA11* in 1 case, *AKT1* in 1 case, *PTEN* in 2 cases and *HRAS* in 1 case. The clinical characteristics and the results of the genetic analysis are summarized in Table 1.

Table 1
Clinical and molecular genetic summary of the patients

Case	Age/Sex	Location	Duration	Clinical diagnosis	Symptom	PIK3CA mutation	Other mutations
1	3/M	Knee	3 years	Infantile hemangioma	Pain, increased swelling	p.H1047R	<i>PTEN</i> (c.63dupG)
2	15/M	Thigh muscle	3 months (After Sclerotherapy)	Vascular malformation	Pain, functional restriction, increased swelling,	p.H1047R	<i>TEK</i> (p.W189*), <i>GNA11</i> (p.E191K), <i>AKT1</i> (p.R15Q, p.Y229=), <i>PTEN</i> (c.63dupG), <i>HRAS</i> (p.R102W)
3	13/M	Thigh muscle	13 years	Venous malformation	Pain, increased swelling	No mutation	No mutation
4	12/M	Thigh muscle	6 months	Venous malformation or FAVA	Pain, functional restriction	No mutation	<i>TEK</i> (p.R842H)
5	72/F	Soleus muscle	Some decades (unclear)	Vascular malformation	Pain, increased swelling	No mutation	No mutation
<i>PIK3CA</i> ; phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha, <i>TEK</i> ; <i>TEK</i> receptor tyrosine kinase, <i>AKT1</i> ; <i>AKT</i> serine/threonine kinase 1, <i>PTEN</i> ; phosphatase and tensin homolog, <i>HRAS</i> , <i>HRas</i> proto-oncogene, GTPase.							

Histological And Immunohistochemical Findings

The PIK3CA-mutation cases (cases 1 and 2) (Fig. 2A-D) and PIK3CA-wt cases (cases 3-5) (Fig. 2E-H) possessed similar histology. All five cases exhibited abnormal vessels surrounded by dense fibrous tissue and adipose tissue with atrophic skeletal muscle (Fig. 2A, E). The abnormal vessels were composed of VM and LM (Fig. 2B, F). The majority of the LM components possessed vascular clusters consisting of thin-walled back-to-back blood-filled sacs (Fig. 2C, G). The lymphatic phenotype was supported by endothelial D2-40 and/or Prox1 immunopositivity in consistent with our previous study [3]. In one PIK3CA-mutant case (case 2) and one PIK3CA-wt case (case 3), some nerves contained enlarged vessels (Fig. 2D, H). The endothelial cells of these vessels within nerves were positive for CD31 (marker for endothelial cells) and CD34 (marker for blood vessels), negative to weakly positive for PROX1 (marker for lymphatic vessels), and negative for D2-40 (marker for lymphatic vessels) (Fig. 2I). That is, the vessels within nerves had the vein-like characteristics. The other findings included the observation of organized thrombi within abnormal veins in three cases (cases 2, 4,

and 5) and lymphocytic aggregates surrounding abnormal vessels in four cases (cases 2-5). The histological findings of all cases are summarized in Table 2.

Table 2
Summary of histological findings

Case	VM	LM	Nerve containing enlarged abnormal vessels	Organized thrombi	Lymphocytic aggregates
1	+	+	-	-	-
2	+	+	+	+	+
3	+	+	+	-	+
4	+	+	-	+	+
5	+	+	-	+	+
VM; venous malformation, LM; lymphatic malformation.					

We next examined the mTOR pathway activation status in abnormal vessels using immunohistochemical staining. The expression of p-AKT and p-mTOR, both of which are upstream of the mTOR pathway, was detected in abnormal vessels of the PIK3CA-mutation cases (cases 1 and 2) (Fig. 3A, B) but not in those of the PIK3CA-wt cases (cases 3-5) (Fig. 3E, F). The expression of p-4EBP1 and p-S6K1, both of which are downstream effectors of the mTOR pathway, was detected in abnormal vessels of both PIK3CA-mutation and PIK3CA-wt cases (Fig. 3C, D, G, H). In normal tissues, including the surrounding skeletal muscle and normal vessels, p-S6K1 exhibited sporadic expression, while p-AKT, p-mTOR, and p-4EBP1 were not expressed at detectable levels. The immunohistochemical results are summarized in Table 3.

Table 3
Immunohistochemical expression of mTOR pathway in abnormal vessels.

Case	p-AKT	p-mTOR	p-4EBP1	p-S6K1
1	+	+	+	+
2	+	+	+	+
3	-	-	+	+
4	-	-	-	+
5	-	-	+	+
Staining intensity (-; no expression / +; positive).				

Discussion

FAVA is a new entity of vascular anomaly and is exceedingly rare. Alomari *et al.* (2014) [1] provided a proposed definition of the clinical and histological characteristics of FAVA. Subsequently, *PIK3CA* mutations were reported in a subset of FAVAs (5/8 cases) [4]. However, the correlations between specific mutations and

clinicopathological features remain unclear. The current study is the first reported series of clinical, histological, immunohistochemical, and genetic analyses examining FAVA cases.

According to a clinical series of FAVA, FAVA arises in young patients (median age, 12-17 years) [1, 2]. Common symptoms include pain (100%), functional restriction (81%-100%), and swelling (36.5%) [1, 2]. The most common location of the lesion is the lower extremities (94.7%) [2]. Our current study determined that the median age of *PIK3CA*-mutation patients was 9 years and that of *PIK3CA*-wt patients was 13 years. Both *PIK3CA*-mutation and *PIK3CA*-wt patients presented with pain, swelling, and functional restriction. All five lesions were located in the lower extremities. Based on the above findings, our cases exhibited typical clinical features regardless of *PIK3CA* mutational status (Table 1) [1, 2]. Similarly, both *PIK3CA*-mutation and *PIK3CA*-wt cases exhibited the typical histological features of FAVA (Table 2). Histologically, VM, LM, fibrous tissue, and adipose tissue were observed in all cases. Nerves containing enlarged vessels, a condition that is unusual in other vascular anomalies, were also present regardless of *PIK3CA* mutational status (Fig. 2D, H). Thus, our observations indicated that there was no significant association between the presence of *PIK3CA* mutations and the clinicopathological features of FAVA.

Immunohistochemical analysis showed that p-AKT and p-mTOR that act upstream of the mTOR pathway were detected in abnormal vessels of *PIK3CA*-mutation cases, but not in those of *PIK3CA*-wt cases (Table 3). On the other hand, p-4EBP1 and p-S6K1, downstream of the mTOR pathway, were detected in abnormal vessels of both *PIK3CA*-mutation and *PIK3CA*-wt cases (Table 3). One interpretation of this discrepancy was that 4EBP1 and S6K1 were activated in mTOR-independent manner. In fact, phosphorylation of 4EBP1 and S6K1 is subject to mTOR-independent several kinases and feedback loops [14, 15]. Somatic mutations in *PIK3CA* occur frequently in cancers other than LMs and other *PIK3CA*-related overgrowth spectrums [4–6, 8]. In cancers, a small number of studies have demonstrated a positive correlation between *PIK3CA* mutations status and upstream activation of the mTOR pathway [16–18]. p-AKT and p-mTOR were immunohistochemically expressed more frequently in *PIK3CA*-mutation cases than in *PIK3CA*-wt cases, while the immunohistochemical expression of p-4EBP1 and p-S6K1 was not correlated with the presence of *PIK3CA* mutation [16–18]. These results were consistent with the relationship between the mutation and immunohistochemical expression in our FAVA cases.

Both 4EBP1 and S6K1 are involved in the development of abnormal vessels in VMs and LMs by promoting protein synthesis and cell growth [5–9, 11, 12]. The activation of 4EBP1 and S6K1 may play a key role in the pathogenesis of abnormal vessels in FAVA lesions, however it was unclear what signaling pathways were involved in their activation. Since the identification of *PIK3CA* mutations in FAVA by Luks et al. [4], further mutational analyses of FAVA have not been performed. Our targeting NGS failed to identify common gene mutations associated with mTOR pathway among *PIK3CA*-wt cases, although *TEK* mutation (p.R842H within exon 13) was detected in one *PIK3CA*-wt case. Somatic gain-of-function mutations in *TEK* gene that encodes the endothelial tyrosine-protein kinase receptor TIE-2 occurs approximately half of sporadic VMs and in a subset of LMs [8, 19, 20]. *TEK* hotspot mutations are detected exclusively in exon 17 and are present within the first tyrosine kinase and kinase insert domains of the receptor [8, 19, 20]. *TEK* hotspot mutations result in a constantly active PI3K/AKT signaling pathway involving angiogenesis [8, 19, 20]. On the other hand, AKT phosphorylates many downstream molecules involved in the regulation of cellular functions. Therefore, little is known about the association with *TEK* mutations and activation of mTOR downstream effectors in VMs. The

identified *TEK* p.R842H (c.2525G>A) mutation in current study is reported in the COSMIC (Catalogue of Somatic Mutations in Cancer) database, however the function of this mutation is not investigated. Considering that activated AKT was not detected in *PIK3CA*-wt cases, the *TEK* p.R842H mutation may not activate AKT in FAVA. Approximately 25 % of VMs lacked both *TEK* and *PIK3CA* mutations [8, 10], and its responsible gene remained unclear. Thus, FAVA lacking *PIK3CA* mutations would be caused by undiscovered mutations that activate 4EBP1 and S6K1.

Conclusions

In this study, we reported the results of clinical, histological, immunohistochemical, and genetic analyses examining a small series of isolated FAVA. There was no significant association between the presence of *PIK3CA* mutations and the clinical and histological features of FAVA, suggesting that the *PIK3CA* gene may be not necessarily involved in the onset of FAVA. FAVA lacking *PIK3CA* mutations would be caused by other mutations that activate 4EBP1 and S6K1.

List Of Abbreviations

4EBP1: Eukaryotic translation initiation factor 4E-binding protein

AKT1: AKT serine/threonine kinase 1

BRAF: B-Raf proto-oncogene, serine/threonine kinase

FAVA: Fibro-adipose vascular anomaly

FFPE: Formalin-fixed paraffin-embedded

GNA11: G protein subunit alpha 11

GNAQ: G protein subunit alpha q

HRAS: HRas proto-oncogene, GTPase

KRAS: KRAS proto-oncogene, GTPase

KTS: Klippel-Trenaunay syndrome

LM: Lymphatic malformation

MAP3K3: Mitogen-activated protein kinase kinase kinase 3

mTOR: Mammalian target of rapamycin

NRAS: NRAS proto-oncogene, GTPase

PCR: Polymerase chain reaction

PI3K: Phosphoinositide 3-kinase

PIK3CA: Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha

PTEN: Phosphatase and tensin homolog

RASA1: RAS p21 protein activator 1

S6K1: Ribosomal protein S6 kinase 1

TEK: TEK receptor tyrosine kinase

VM: Venous malformation

WT: Wild-type

Declarations

Ethics approval and consent to participate

This study was approved by the Ethical Review Board of the Graduate School of Medicine, Osaka University (No. 17214), and was performed in accordance with the Committee guidelines and regulations.

Consent for publication

Written informed consent for publication of their clinical details and clinical images was obtained from the patients. A copy of the consent form is available for review by the Editor of this journal.

Availability of data and materials

The surgical materials and the datasets analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no conflicts of interest.

Funding

This work was supported by JSPS KAKENHI (21K15384) and Practical Research Project for Rare / Intractable Diseases (21ek0109515h0001) from Japan's Agency for Medical Research and Development, AMED

Author's contributions

All authors contributed to this work. Yumiko H. and Katsutoshi H. participated in the concept of this study and wrote the manuscript. These two authors contributed equally to this work. Yumiko H., Katsutoshi H., Michio O., Kenji H., Daisuke M., Shinichiro T., Takahiro M., Masaharu K. and Satoru T. performed the experiments and assembled data. Yumiko H., Katsutoshi H. and Eiichi M. were critically revised the manuscript for intellectual

content. Hiroki H., Yusuke O. and Kaishu T. reviewed the clinical and radiological data. All authors reviewed and approved the manuscript for submission.

Acknowledgements

Not applicable.

References

1. Alomari AI, Spencer SA, Arnold RW, et al. Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity. *J Pediatr Orthop*. 2014;34:109–17.
2. Amarneh M, Shaikh R. Clinical and imaging features in fibro-adipose vascular anomaly (FAVA). *Pediatr Radiol*. 2020;50:380–87.
3. Hori Y, Hirose K, Aramaki-Hattori N, et al. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway. *Diagn Pathol*. 2020;15:98.
4. Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. *J Pediatr*. 2015;166:1048-54.e1-5.
5. Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. *Trends Mol Med*. 2018;24:856–70.
6. Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. *Am J Med Genet A*. 2015;167A:287–95.
7. Blesinger H, Kaulfuß S, Aung T, et al. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. *PLoS One*. 2018;13:e0200343.
8. Castillo SD, Baselga E, Graupera M. PIK3CA mutations in vascular malformations. *Curr Opin Hematol*. 2019;26:170–78.
9. Castel P, Carmona FJ, Grego-Bessa J, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. *Sci Transl Med*. 2016;8:332ra42.
10. Limaye N, Kangas J, Mendola A, et al. Somatic Activating PIK3CA Mutations Cause Venous Malformation. *Am J Hum Genet*. 2015;97:914–21.
11. Whalen SG, Gingras AC, Amankwa L, et al. Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins. *J Biol Chem*. 1996;271:11831–7.
12. Dennis PB, Pullen N, Kozma SC, et al. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. *Mol Cell Biol*. 1996;16:6242–51.
13. Zenner K, Cheng CV, Jensen DM, et al. Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations. *JCI Insight*. 2019;4:e129884.
14. Qin X, Jiang B, Zhang Y. 4E-BP1, a multifactor regulated multifunctional protein. *Cell Cycle*. 2016;15:781–86.
15. Arif A, Jia J, Willard B, Li X, Fox PL. Phosphorylation of S6K1 directs a kinase phospho-code that determines substrate selection. *Mol Cell*. 2019;73:446–57.

16. Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. *Clin Cancer Res*. 2007;13(2 Pt 1):408–14.
17. Azim HA, Kassem L, Treilleux I, et al. Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. *Transl Oncol*. 2016;9:114–23.
18. Wang J, Zhu X, Xu X, et al. PIK3CA mutations and downstream effector p-mTOR expression: implication for prognostic factors and therapeutic targets in triple negative breast cancer. *Int J Clin Exp Pathol*. 2017;10:7682–91.
19. Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. *Nat Genet*. 2009;41:118–24.
20. Ye C, Pan L, Huang Y, Ye R, Han A, Li S, Li X, Wang S. Somatic mutations in exon 17 of the TEK gene in vascular tumors and vascular malformations. *J Vasc Surg*. 2011;54:1760–8.

Figures

Figure 1

A-E Computed Tomography (CT) or magnetic resonance image (MRIs) analysis. Sagittal CT image of case 1 (A), and axial T2-weighted MRI of case 2 (B), case 3 (C), case 4 (D) and case 5 (E). F, G DNA sanger sequencing of hotspot mutations in PIK3CA. Sequencing of PIK3CA for each FAVA cases showing chromatograms for c.3140A>G (p.H1047R) (F) or wild-type (G).

Figure 2

Histology and immunohistochemical analysis of FAVA. A-H Representative histological findings in PIK3CA-mutation case (A-D) and PIK3CA-wild type (wt) case (E-H). Vascular malformation and adipose and dense fibrous tissue (A, E; lower magnification and B, F; higher magnification). Clusters of vascular channels with thin-walled back-to-back blood-filled sacs (C, G). Nerve containing enlarged vessels (D, H arrows). I Serial sections of a nerve containing enlarged vessels (H) stained for S100, CD31, CD34, PROX1, and D2-40 (arrows indicated abnormal vessels in nerve).

Figure 3

Immunohistochemical expression of the mTOR pathway in abnormal vessels of FAVA. A-H Representative immunohistochemical staining patterns of abnormal vessels in PIK3CA-mutation case (A-D) and PIK3CA-wild type (wt) case (E-H). Abnormal vessels expressed phosphorylated AKT (p-AKT), phosphorylated mammalian target of rapamycin (p-mTOR), phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 (p-4EBP1), and phosphorylated ribosomal protein S6 kinase 1 (p-S6K1) in the PIK3CA-mutation case but did not express p-AKT and p-mTOR in the PIK3CA-wt case.